User login
Key clinical point: Among malignancies, including breast cancer, melanoma, lymphoma, and non-melanoma skin cancer (NMSC), patients with moderate-to-severe atopic dermatitis (AD) had the highest incidence rate (IR) for NMSC followed by breast cancer and melanoma; NMSC incidence increased with age among patients with moderate but not severe AD.
Major finding: In patients with moderate and severe AD, the IR per 1000 person-years were 4.6 (95% CI 3.9-5.5) and 5.9 (95% CI 3.8-9.2) for NMSC, 2.2 (95% CI 1.6-3.0) and 0.5 (95% CI 0.1-3.9) for breast cancer, and 0.4 (95% CI 0.2-0.7) and 0.6 (95% CI 0.1-2.3) for melanoma, respectively. The NMSC IR increased with increasing age in patients with moderate AD (18-39 vs ≥65 years: 0.1 [95% CI 0.0-0.7] vs 18.0 [95% CI 13.9-23.2]).
Study details: This retrospective study analyzed the data of 7050 adults with moderate-to-severe AD from the Kaiser Permanente Northern California database.
Disclosures: This study was sponsored by Pfizer Inc. Some authors reported ties with various organizations, including Pfizer.
Source: Hedderson MM et al. Rates of malignancies among patients with moderate to severe atopic dermatitis: A retrospective cohort study. BMJ Open. 2023;13(3):e071172 (Mar 10). Doi: 10.1136/bmjopen-2022-071172
Key clinical point: Among malignancies, including breast cancer, melanoma, lymphoma, and non-melanoma skin cancer (NMSC), patients with moderate-to-severe atopic dermatitis (AD) had the highest incidence rate (IR) for NMSC followed by breast cancer and melanoma; NMSC incidence increased with age among patients with moderate but not severe AD.
Major finding: In patients with moderate and severe AD, the IR per 1000 person-years were 4.6 (95% CI 3.9-5.5) and 5.9 (95% CI 3.8-9.2) for NMSC, 2.2 (95% CI 1.6-3.0) and 0.5 (95% CI 0.1-3.9) for breast cancer, and 0.4 (95% CI 0.2-0.7) and 0.6 (95% CI 0.1-2.3) for melanoma, respectively. The NMSC IR increased with increasing age in patients with moderate AD (18-39 vs ≥65 years: 0.1 [95% CI 0.0-0.7] vs 18.0 [95% CI 13.9-23.2]).
Study details: This retrospective study analyzed the data of 7050 adults with moderate-to-severe AD from the Kaiser Permanente Northern California database.
Disclosures: This study was sponsored by Pfizer Inc. Some authors reported ties with various organizations, including Pfizer.
Source: Hedderson MM et al. Rates of malignancies among patients with moderate to severe atopic dermatitis: A retrospective cohort study. BMJ Open. 2023;13(3):e071172 (Mar 10). Doi: 10.1136/bmjopen-2022-071172
Key clinical point: Among malignancies, including breast cancer, melanoma, lymphoma, and non-melanoma skin cancer (NMSC), patients with moderate-to-severe atopic dermatitis (AD) had the highest incidence rate (IR) for NMSC followed by breast cancer and melanoma; NMSC incidence increased with age among patients with moderate but not severe AD.
Major finding: In patients with moderate and severe AD, the IR per 1000 person-years were 4.6 (95% CI 3.9-5.5) and 5.9 (95% CI 3.8-9.2) for NMSC, 2.2 (95% CI 1.6-3.0) and 0.5 (95% CI 0.1-3.9) for breast cancer, and 0.4 (95% CI 0.2-0.7) and 0.6 (95% CI 0.1-2.3) for melanoma, respectively. The NMSC IR increased with increasing age in patients with moderate AD (18-39 vs ≥65 years: 0.1 [95% CI 0.0-0.7] vs 18.0 [95% CI 13.9-23.2]).
Study details: This retrospective study analyzed the data of 7050 adults with moderate-to-severe AD from the Kaiser Permanente Northern California database.
Disclosures: This study was sponsored by Pfizer Inc. Some authors reported ties with various organizations, including Pfizer.
Source: Hedderson MM et al. Rates of malignancies among patients with moderate to severe atopic dermatitis: A retrospective cohort study. BMJ Open. 2023;13(3):e071172 (Mar 10). Doi: 10.1136/bmjopen-2022-071172